Practice | Five things to know about ...

Hyperferritinemia

Alexander Kumachev MD MSc, David W. Frost MD

Cite as: CMAJ 2021 October 4;193:E1534. doi: 10.1503/cmaj.210359

1 Ferritin is a cellular iron storage protein and an acute phase reactant

Clinicians obtain ferritin levels when they suspect iron deficiency or overload; they may also obtain ferritin levels during the work-up of some hematologic or autoimmune conditions.¹⁻⁴ Levels may be elevated in many chronic conditions (Box 1) or during acute illness, which can confound interpretation.² Levels that return to normal after resolution of illness do not require further investigation.

2 Transferrin saturation testing can identify iron overload states

If the transferrin saturation is above 45% and ferritin levels are greater than 300 μ g/L in men or than 200 μ g/L in women, genetic testing should be done to assess for hemochromatosis.⁴ Secondary causes of iron overload (e.g., iron-loading anemias, exogenous iron administration) can also have elevated transferrin saturation. Hyperferritinemia without elevated transferrin saturation suggests an alternate cause.^{2,4}

3 Ferritin elevations above 10 000 μg/L should prompt consideration of specific diagnoses

Although elevations above 10000 μ g/L may be seen in malignant disease, chronic kidney disease or liver dysfunction,^{3–5} high levels could also suggest adult-onset Still disease and hemophagocytic lymphohistiocytosis in acutely ill patients with suggestive features (e.g., fever, hepatosplenomegaly, rash, neurologic findings, pancytopenia).^{1,5}

4 Patient history and examination should guide additional investigations

Further testing may include evaluating markers of inflammation and autoimmune disease, serologic evidence of infection and ultrasonography of the liver. Alcohol intake and risk factors for metabolic syndrome should also be reviewed.^{2,3}

5 Patients with stable, mild ferritin elevation do not require further testing

Patients with serum ferritin levels below 1000 μ g/L without an elevated transferrin saturation or clear underlying cause should be counselled about alcohol cessation and dietary changes aimed at managing metabolic syndrome. Stable repeat levels at 3–6 months do not require additional testing.² Ferritin levels persistently above 1000 μ g/L without a clear cause should be investigated further by a general internist or hepatologist.^{3,4}

References

- 1. Knovich MA, Storey JA, Coffman LG. Ferritin for the clinician. *Blood Rev* 2009;23:95-104.
- Cullis JO, Fitzsimons EJ, Griffiths WJ, et al. Investigation and management of a raised serum ferritin. Br J Haematol 2018;181:331-40.
- 3. Adams PC, Barton JC. A diagnostic approach to hyperferritinemia with a non-elevated transferrin saturation. *J Hepatol* 2011;55:453-8.
- Kowdley KV, Brown KE, Ahn J, et al. ACG clinical guideline: hereditary hemochromatosis. Am J Gastroenterol 2019;114:1202-18.
- Senjo H, Higuchi T, Okada S, et al. Hyperferritinemia: causes and significance in a general hospital. Hematology 2018;23:817-22.

Box 1: Causes of hyperferritinemia.¹⁻⁴

Alcohol use

- Alcoholic and nonalcoholic fatty liver disease
- Chronic kidney disease
- Hematologic causes
 - Thalassemia
 - Chronic hemolytic anemia
 - Sickle cell anemia
 - Parenteral iron overload or red blood cell transfusions
 - Myelodysplastic syndromes
- Hemochromatosis
- Infectious causes
- Viral hepatitis
- HIV
- Osteomyelitis
- Inflammatory causes
 - Connective tissue disorders
 - Rheumatoid arthritis
- Metabolic syndrome
- Neoplastic causes
 - Solid organ and hematologic malignant diseases

Competing interests: None declared.

This article has been peer reviewed.

Affiliations: Department of Medicine (Kumachev, Frost), and Division of Clinical Pharmacology & Toxicology (Kumachev), University of Toronto; Division of General Internal Medicine (Frost), University Health Network, Toronto, Ont.

Funding: Dr. Frost is supported by the Dr. Herbert Ho Ping Kong Chair in General Internal Medicine, University Health Network, University of Toronto.

Content licence: This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0) licence, which permits use, distribution and reproduction in any medium, provided that the original publication is properly cited, the use is noncommercial (i.e., research or educational use), and no modifications or adaptations are made. See: https://creativecommons. org/licenses/by-nc-nd/4.0/

Correspondence to: Alexander Kumachev, alex.kumachev@mail.utoronto.ca

© 2021 CMA Joule Inc. or its licensors

Downloaded for Anonymous User (n/a) at Region of Southern Denmark from ClinicalKey.com by Elsevier on November 29, 2021. For personal use only. No other uses without permission. Copyright ©2021. Elsevier Inc. All rights reserved.